Last updated: July 28, 2026 · By NooBlue Editorial · Published July 28, 2026 · 9 peer-reviewed sources
Key statistics
- 0.5–4 mg/kg — the low-dose range where the published memory and mitochondrial effects are reported (Rojas JC et al., Prog Neurobiol 2012)
- Hormetic, not linear — methylene blue shows opposite effects at low versus high doses, one of the few nootropic compounds where more is measurably worse (Rojas JC et al., Prog Neurobiol 2012)
- 0.07 µM — the concentration at which methylene blue half-inhibits human MAO-A in vitro, making it a potent reversible MAO-A inhibitor (Delport A et al., Toxicol Appl Pharmacol 2017)
- 0.75 mg/kg IV produced a 500 ng/mL (1.6 µM) peak plasma concentration — above the level that inhibits MAO-A, which is why the SSRI interaction is a hard contraindication rather than a caution (Gillman PK et al., J Psychopharmacol 2011)
- 13 of 14 reported cases of methylene-blue CNS toxicity met the Hunter Serotonin Toxicity Criteria (Gillman PK et al., J Psychopharmacol 2011)
- Complex IV is the target — methylene blue reroutes electrons from NADH directly to cytochrome c, bypassing complexes I/III (Tucker D et al., Mol Neurobiol 2018)
Methylene blue is discussed constantly in the nootropics and longevity space, and almost always without numbers. This report collects the figures that actually appear in the peer-reviewed literature — dose ranges, the concentration at which it inhibits monoamine oxidase A, the plasma levels reached at clinical doses, and where research activity is concentrated — into one citable reference. Every number below is traceable to a specific paper listed in the methodology section.
Table of contents
- 1 What doses of methylene blue appear in the published research?
- 2 What does methylene blue actually do in the mitochondria?
- 3 Why does the dose-response curve matter more here than with other supplements?
- 4 What does the research say about the SSRI interaction?
- 5 Where is methylene blue research actually concentrated?
- 6 How to read a methylene blue study without being misled
- 7 Methodology & sources
- 8 How long has methylene blue actually been in clinical use?
- 9 What does the research NOT show?
- 10 Frequently asked questions
What doses of methylene blue appear in the published research?
The low-dose range reported for memory and mitochondrial effects is roughly 0.5–4 mg per kilogram of body weight. That is the band Rojas JC et al., Prog Neurobiol 2012 identify in their review of methylene blue’s neurometabolic mechanisms — and the qualifier “low-dose” is doing real work, because the same review documents that the compound’s effects reverse at higher concentrations.
| Context | Dose / concentration reported | Source |
|---|---|---|
| Low-dose range associated with memory and neuroprotective effects | 0.5–4 mg/kg | Rojas JC et al., Prog Neurobiol 2012 |
| IV dose shown to produce MAO-A-inhibiting plasma levels | 0.75 mg/kg → 500 ng/mL (1.6 µM) peak | Gillman PK et al., J Psychopharmacol 2011 |
| IV dose at which severe serotonin toxicity has occurred in humans | 1 mg/kg | Gillman PK et al., J Psychopharmacol 2011 |
| Clinical IV dosing range across methemoglobinemia, vasoplegia and parathyroid surgery | 1–7.5 mg/kg | Gillman PK et al., J Psychopharmacol 2011 |
| In vitro MAO-A half-inhibition concentration (IC₅₀) | 0.07 µM | Delport A et al., Toxicol Appl Pharmacol 2017 |
Two things are worth noticing in that table. First, the clinical intravenous doses used in hospital settings (1–7.5 mg/kg) sit far above the low-dose band discussed in the cognitive literature. Second, the dose that produced serotonin toxicity in humans — 1 mg/kg — falls inside the clinical range, which is exactly why the interaction discussed below is treated as a contraindication rather than a footnote.
For how these figures translate into consumer supplement servings, see our methylene blue dosage guide.
What does methylene blue actually do in the mitochondria?
It acts as an alternative electron carrier, rerouting electrons from NADH directly to cytochrome c and bypassing complexes I and III of the electron transport chain. Tucker D et al., Mol Neurobiol 2018 describe this mechanism and note that it increases complex IV activity while mitigating oxidative stress.
This is the structural reason methylene blue behaves differently from most compounds marketed for energy or focus. It does not stimulate a receptor. Rojas JC et al., Prog Neurobiol 2012 make the point explicitly: methylene blue’s effects “are not determined by regular drug-receptor interactions or drug-response paradigms” — it functions as a redox agent in the respiratory chain itself. Gonzalez-Lima F et al., Biochem Pharmacol 2014 place this in a wider frame, treating mitochondrial respiration as a therapeutic target and describing low-dose USP methylene blue as one of three interventions (alongside photobiomodulation and ketogenic approaches) that improve brain mitochondrial respiration.
Why does the dose-response curve matter more here than with other supplements?
Because it is hormetic: low and high doses produce opposite effects. Rojas JC et al., Prog Neurobiol 2012 state this directly, and it is the single most important fact for anyone using methylene blue outside a clinical setting. With most supplements, an excessive dose is wasteful. With methylene blue, the published mechanism reverses — the antioxidant, respiration-enhancing behaviour observed at low concentrations does not simply plateau at higher ones.
This is why precision dosing and verified concentration matter more for this compound than for almost anything else in a supplement cabinet, and why we publish a Certificate of Analysis for every batch. Our purity and grading guide explains what USP grade means in practice.
What does the research say about the SSRI interaction?
Methylene blue is a potent, reversible inhibitor of monoamine oxidase A — the finding Ramsay RR et al., Br J Pharmacol 2007 confirmed with kinetic assays on purified human MAO, showing tight binding to MAO-A and much weaker inhibition of MAO-B. Delport A et al., Toxicol Appl Pharmacol 2017 later quantified the potency at an IC₅₀ of 0.07 µM for MAO-A.
The clinical consequence is documented by Gillman PK et al., J Psychopharmacol 2011: of 14 reported cases of methylene-blue CNS toxicity reviewed, 13 met the Hunter Serotonin Toxicity Criteria. The same review reports that an intravenous dose of only 0.75 mg/kg produced a peak plasma concentration of 500 ng/mL (1.6 µM) — enough to inhibit MAO-A centrally — and concludes that essentially all proposed uses of methylene blue reach MAO-blocking levels.
In plain terms: if you take an SSRI, SNRI, or another serotonergic medication, methylene blue is not a supplement to experiment with. Our side effects guide covers the full interaction picture, and this is a conversation to have with your doctor rather than a forum.
Where is methylene blue research actually concentrated?
The published literature clusters in a few areas, and the balance is informative:
| Research area | What the literature reports | Representative source |
|---|---|---|
| Memory & cognitive enhancement | Memory-enhancing effects tied to improved memory consolidation, network-specific and use-dependent | Rojas JC et al., Prog Neurobiol 2012 |
| Neurodegeneration & neuroprotection | Efficacy reported in animal models of stroke, cerebral ischemia, Alzheimer’s, Parkinson’s, and traumatic brain injury | Tucker D et al., Mol Neurobiol 2018 |
| Alzheimer’s disease specifically | Reported attenuation of amyloid plaque and neurofibrillary tangle formation; effects on cholinergic, serotonergic and glutamatergic systems | Oz M et al., Biochem Pharmacol 2009 |
| Neuropsychiatric use | Antidepressant and anxiolytic properties documented in animal and human studies; results reported in bipolar disorder | Alda M et al., CNS Drugs 2019 |
| Ageing & skin | Reviewed for age-related conditions including neurodegeneration, memory loss, skin ageing and progeria | Xue H et al., Cells 2021 |
| Safety / interactions | MAO-A inhibition and serotonin toxicity risk | Ramsay RR et al., Br J Pharmacol 2007, Gillman PK et al., J Psychopharmacol 2011 |
An honest reading: a large share of the neuroprotection evidence comes from animal models, while the human evidence base is strongest on the safety side — specifically on the MAO-A interaction. Alda M et al., CNS Drugs 2019 note methylene blue has been used in psychiatry “for over a century,” which is unusual for a compound the supplement market treats as new.
How to read a methylene blue study without being misled
Most confusion about this compound comes from three reading errors, all of which the sources above make easy to avoid.
1. Check the administration route before comparing doses. The figures that generate alarming headlines — serotonin toxicity at 1 mg/kg — come from intravenous administration in clinical settings (Gillman, J Psychopharmacol 2011). Oral administration produces different absorption and first-pass behaviour; Ramsay and colleagues specifically flag “implications for gut uptake of amines when administered orally” as a distinct consideration. A milligram figure without a route attached is not a comparable number.
2. Separate in vitro concentrations from in vivo doses. The 0.07 µM MAO-A inhibition figure (Delport et al., Toxicol Appl Pharmacol 2017) describes purified enzyme in a dish, not a dose you take. It becomes decision-relevant only alongside the plasma-concentration data showing that clinical doses actually reach MAO-inhibiting levels in the body.
3. Note whether a paper is a review or a primary study. Six of the nine sources in this report are reviews — valuable for synthesis, but they aggregate other people’s data rather than generating new results. When a claim traces back only to reviews citing animal work, the honest description is “studies suggest,” not “research shows.”
Applied together, these three checks explain why the practical takeaways from this literature are narrow: use the low end of the researched range, verify what is actually in the bottle, and treat the SSRI interaction as an absolute rather than a probability.
Methodology & sources
How this report was built. Sources were retrieved from PubMed on 28 July 2026 using searches for methylene blue in combination with cognition/memory (restricted to human studies), clinical-trial publication types, and serotonin toxicity/monoamine oxidase terms. Every figure quoted above appears in the abstract or body of the cited paper; no value has been estimated, averaged across studies, or carried over from secondary sources. Where a paper is a review rather than a primary trial, it is described as a review in the text. Dose figures are reported as the source states them (mg/kg body weight, plasma ng/mL, or in vitro µM) and are deliberately not converted into consumer serving sizes — that conversion depends on formulation and is a decision for a healthcare professional.
What this report is not. It is a summary of published literature, not medical advice, and not a claim that methylene blue treats any condition. Much of the neuroprotection research cited is preclinical. Studies suggest the effects described; they do not establish outcomes for any individual.
Full source list (all links go to PubMed):
- Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32-45. PMID: 22067440. DOI: 10.1016/j.pneurobio.2011.10.007
- Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007;152(6):946-51. PMID: 17721552. DOI: 10.1038/sj.bjp.0707430
- Gillman PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol. 2011;25(3):429-36. PMID: 20142303. DOI: 10.1177/0269881109359098
- Gonzalez-Lima F, Barksdale BR, Rojas JC. Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. Biochem Pharmacol. 2014;88(4):584-93. PMID: 24316434. DOI: 10.1016/j.bcp.2013.11.010
- Tucker D, Lu Y, Zhang Q. From Mitochondrial Function to Neuroprotection – an Emerging Role for Methylene Blue. Mol Neurobiol. 2018;55(6):5137-5153. PMID: 28840449. DOI: 10.1007/s12035-017-0712-2
- Xue H, Thaivalappil A, Cao K. The Potentials of Methylene Blue as an Anti-Aging Drug. Cells. 2021;10(12):3379. PMID: 34943887. DOI: 10.3390/cells10123379
- Alda M. Methylene Blue in the Treatment of Neuropsychiatric Disorders. CNS Drugs. 2019;33(8):719-725. PMID: 31144270. DOI: 10.1007/s40263-019-00641-3
- Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease. Biochem Pharmacol. 2009;78(8):927-32. PMID: 19433072. DOI: 10.1016/j.bcp.2009.04.034
- Delport A, Harvey BH, Petzer A, Petzer JP. The monoamine oxidase inhibition properties of selected structural analogues of methylene blue. Toxicol Appl Pharmacol. 2017;325:1-8. PMID: 28377303. DOI: 10.1016/j.taap.2017.03.026
Citation data retrieved from PubMed. If you cite this report, please also cite the underlying papers directly.
How long has methylene blue actually been in clinical use?
Longer than almost any drug still in circulation. Methylene blue was the first fully synthetic medicine, and its documented clinical applications span malaria treatment, methemoglobinemia, carbon monoxide poisoning, and use as a histological stain (Xue et al., Cells 2021; Tucker et al., Mol Neurobiol 2018). In psychiatry specifically, Alda, CNS Drugs 2019 notes it has been used “for over a century.”
That history matters for how you read the current wave of interest. Methylene blue is not a novel compound with an unknown safety profile — the mitochondrial mechanism is what is new to attention, not the molecule. Tucker and colleagues frame the renewed interest precisely that way: a well-established drug “with a long history of use, owing to its diverse range of use and its minimal side effect profile,” whose mitochondrial role “elicited much of its renewed interest in recent years.” The flip side is that a century of clinical use is also how the MAO-A interaction came to be so well characterised: the serotonin-toxicity cases were observed in hospital settings at clinical intravenous doses, not inferred from theory.
What does the research NOT show?
Reports like this are more useful when they mark the boundaries of the evidence rather than only the highlights. Four honest gaps stand out in the sources collected here:
- Most neuroprotection evidence is preclinical. The efficacy reported across stroke, cerebral ischemia, Alzheimer’s, Parkinson’s and traumatic brain injury comes from in vitro and in vivo animal models (Tucker et al., 2018). Animal-model efficacy is a reason to run human trials, not a substitute for them.
- There is no established consumer dose. The 0.5–4 mg/kg band appears in the research literature; it is not a consumer serving recommendation, and the papers do not translate it into one. Anyone quoting a precise “optimal daily dose” for supplementation is going beyond what these sources support.
- Long-term supplementation data is thin. The clinical history is largely acute or short-course use (methemoglobinemia, surgical applications). Multi-year daily low-dose supplementation in healthy adults is not what the century of clinical experience covers.
- Effects are context-dependent. Rojas et al., 2012 describe the memory effects as network-specific and use-dependent — improving memory consolidation under particular conditions, not producing a uniform cognitive lift.
None of this makes the compound uninteresting. It makes the difference between low-dose and high-dose, and between verified and unverified product, the two variables actually worth controlling — which is where a published Certificate of Analysis and precise milligram dosing stop being marketing language and start being the practical application of the research.
Frequently asked questions
What dose of methylene blue is used in research?
The low-dose range associated with memory and mitochondrial effects in the literature is approximately 0.5–4 mg per kilogram of body weight. Clinical intravenous doses in hospital settings run higher, from 1 to 7.5 mg/kg depending on indication.
Is methylene blue an MAO inhibitor?
Yes. Kinetic assays on purified human enzyme confirmed methylene blue is a potent, reversible inhibitor of monoamine oxidase A, with a reported IC₅₀ of 0.07 µM; it inhibits MAO-B only at much higher concentrations. This is the mechanism behind the documented serotonin-toxicity cases when combined with serotonergic medication.
Why is methylene blue described as hormetic?
Because low and high doses produce opposite effects. At low concentrations it acts as an electron cycler in the mitochondrial electron transport chain with antioxidant and respiration-enhancing properties; at higher concentrations that behaviour reverses. This makes accurate dosing unusually important compared with most supplements.
How much of the methylene blue research is in humans?
It is mixed. Much of the neuroprotection evidence comes from animal models of stroke, Alzheimer’s, Parkinson’s and traumatic brain injury. The strongest human evidence concerns safety — specifically MAO-A inhibition and the resulting serotonin-toxicity risk — alongside a long history of clinical use in psychiatry and for methemoglobinemia.
